{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,2]],"date-time":"2024-07-02T23:19:05Z","timestamp":1719962345296},"reference-count":83,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T00:00:00Z","timestamp":1417392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Immunology Letters"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1016\/j.imlet.2014.10.008","type":"journal-article","created":{"date-parts":[[2014,10,18]],"date-time":"2014-10-18T11:02:25Z","timestamp":1413630145000},"page":"134-140","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"PB","title":["Clinical immunology \u2013 Autoimmunity in the Netherlands"],"prefix":"10.1016","volume":"162","author":[{"given":"Jan Willem Cohen","family":"Tervaert","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cees G.M.","family":"Kallenberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.imlet.2014.10.008_bib0005","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(14)60128-8","article-title":"Systemic lupus erythematosus","author":"Lisnevskaia","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.imlet.2014.10.008_bib0010","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1056\/NEJMra1100359","article-title":"Systemic lupus erythematosus","volume":"365","author":"Tsokos","year":"2011","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.imlet.2014.10.008_bib0015","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1097\/BOR.0000000000000086","article-title":"Advances in lupus genetics and epigenetics","author":"Deng","year":"2014","journal-title":"Curr Opin Rheumatol"},{"issue":"April","key":"10.1016\/j.imlet.2014.10.008_bib0020","first-page":"164","article-title":"Breaking immunological tolerance in systemic lupus erythematosus","volume":"5","author":"Pieterse","year":"2014","journal-title":"Front Immunol"},{"key":"10.1016\/j.imlet.2014.10.008_bib0025","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1002\/art.22646","article-title":"Apoptosis-induced acetylation of histones is pathogenic in systemic lupus erythematosus","volume":"56","author":"Dieker","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.imlet.2014.10.008_bib0030","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1136\/ard.2010.129320","article-title":"Apoptosis-induced histone H3 methylation is targeted by autoantibodies in systemic lupus erythematosus","volume":"70","author":"van Bavel","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.imlet.2014.10.008_bib0035","doi-asserted-by":"crossref","first-page":"3399","DOI":"10.1002\/art.22947","article-title":"Opsonization of late apoptotic cells by systemic lupus erythematosus autoantibodies inhibits their uptake via an Fc-gamma receptor-dependent mechanism","volume":"56","author":"Reefman","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.imlet.2014.10.008_bib0040","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1136\/ard.2007.070359","article-title":"Type 1 interferons are involved in the development of ultraviolet B-induced inflammatory skin lesions in systemic lupus erythematosus patients","volume":"67","author":"Reefman","year":"2008","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.imlet.2014.10.008_bib0045","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1097\/BOR.0000000000000087","article-title":"Type 1 interferon in the pathogenesis of lupus","author":"Crow","year":"2014","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.imlet.2014.10.008_bib0050","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.coph.2013.04.005","article-title":"New biologic therapy for systemic lupus erythematosus","volume":"13","author":"Ding","year":"2013","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.imlet.2014.10.008_bib0055","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/nrrheum.2011.222","article-title":"HMGB1: a multifunctional alarmin driving autoimmune and inflammatory disease","volume":"8","author":"Harris","year":"2012","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.imlet.2014.10.008_bib0060","doi-asserted-by":"crossref","first-page":"72","DOI":"10.2119\/molmed.2014.00019","article-title":"Recent developments in the role of high-mobility group box 1 in systemic lupus erythematosus","volume":"20","author":"Schaper","year":"2014","journal-title":"Mol Med"},{"key":"10.1016\/j.imlet.2014.10.008_bib0065","doi-asserted-by":"crossref","first-page":"R71","DOI":"10.1186\/ar3332","article-title":"High mobility group box 1 (HMGB1) and anti-HMGB1 antibodies and their relationship to disease characteristics in systemic lupus erythematosus","volume":"13","author":"Abdulahad","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.imlet.2014.10.008_bib0070","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1097\/BOR.0b013e32835cee2d","article-title":"Inhibition of high-mobility group box 1 as therapeutic option in autoimmune disease: lessons from animal models","volume":"25","author":"Schaper","year":"2013","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.imlet.2014.10.008_bib0075","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1002\/art.1780330505","article-title":"Measurement of increases in anti-double stranded DNA antibody levels as a predictor of disease exacerbation in systemic lupus erythematosus","volume":"33","author":"ter Borg","year":"1990","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.imlet.2014.10.008_bib0080","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1172\/JCI117371","article-title":"Anti-nucleosome antibodies complexed to nucleosomal antigens show anti-DNA reactivity and bind to rat glomerular basement membrane in vivo","volume":"94","author":"Kramers","year":"1994","journal-title":"J Clin Invest"},{"key":"10.1016\/j.imlet.2014.10.008_bib0085","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.semnephrol.2011.06.009","article-title":"Lupus Nephritis: role of antinucleosome autoantibodies","volume":"31","author":"van der Vlag","year":"2011","journal-title":"Semin Nephrol"},{"key":"10.1016\/j.imlet.2014.10.008_bib0090","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/0272-6386(95)90595-2","article-title":"Changes in antibodies to C1q predict renal relapses in systemic lupus erythematosus","author":"Coremans","year":"1995","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.imlet.2014.10.008_bib0095","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1172\/JCI200421075","article-title":"Anti-C1q autoantibodies deposit in glomeruli but are only pathogenic in combination with glomerular C1q-containing immune complexes","volume":"114","author":"Trouw","year":"2004","journal-title":"J Clin Invest"},{"key":"10.1016\/j.imlet.2014.10.008_bib0100","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1182\/blood-2012-03-378646","article-title":"The significance of autoantibodies against \u03b22-glycoprotein 1","volume":"120","author":"de Groot","year":"2012","journal-title":"Blood"},{"issue":"Suppl. 3","key":"10.1016\/j.imlet.2014.10.008_bib0105","doi-asserted-by":"crossref","first-page":"S40","DOI":"10.1016\/S0049-3848(11)70011-1","article-title":"Mechanisms of anti-phospholipid antibody formation and action","volume":"127","author":"de Groot","year":"2011","journal-title":"Thromb Res"},{"key":"10.1016\/j.imlet.2014.10.008_bib0110","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1177\/0961203309361483","article-title":"Towards evidence-based treatment of thrombotic antiphospholipid syndrome","volume":"19","author":"Derksen","year":"2010","journal-title":"Lupus"},{"key":"10.1016\/j.imlet.2014.10.008_bib0115","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.clim.2011.08.005","article-title":"Disturbed Th1, Th2, Th17 and Treg balance in patients with systemic lupus erythematosus","volume":"141","author":"Dolff","year":"2011","journal-title":"Clin Immunol"},{"key":"10.1016\/j.imlet.2014.10.008_bib0120","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1136\/ard.2009.124636","article-title":"Urinary T cells in active lupus nephritis show an effector memory phenotype","volume":"69","author":"Dolff","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.imlet.2014.10.008_bib0125","doi-asserted-by":"crossref","first-page":"2877","DOI":"10.1002\/art.20654","article-title":"Selective gray matter damage in neuropsychiatric lupus","volume":"50","author":"Steens","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.imlet.2014.10.008_bib0130","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1002\/art.23452","volume":"58","author":"Emmer","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.imlet.2014.10.008_bib0135","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1038\/sj.ki.5001630","article-title":"Azathioprine\/methylprednisolone versus cyclophosphamide in proliferative lupus nephritis. A randomized controlled trial","volume":"70","author":"Grootscholten","year":"2006","journal-title":"Kidney Int"},{"key":"10.1016\/j.imlet.2014.10.008_bib0140","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1136\/annrheumdis-2011-200384","article-title":"Long-term follow-up of a randomised controlled trial of azathioprine\/methylprednisolone versus cyclophosphamide in patients with proliferative lupus nephritis","volume":"71","author":"Arends","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.imlet.2014.10.008_bib0145","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1136\/annrheumdis-2012-202760","article-title":"Efficacy and safety of epratuzumab in patients with moderate\/severe active systemic lupus erythematosus: results from EMBLEM, a phade IIb, randomised, double-blind, placebo-controlled, multicentre study","volume":"73","author":"Wallace","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.imlet.2014.10.008_bib0150","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1002\/art.30613","article-title":"A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus","volume":"63","author":"Furie","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.imlet.2014.10.008_bib0155","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1136\/ard.2005.043943","article-title":"Safety and efficacy of influenza vaccination in systemic lupus erythematosus patients with quiescent disease","volume":"65","author":"Holvast","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.imlet.2014.10.008_bib0160","doi-asserted-by":"crossref","first-page":"2438","DOI":"10.1002\/art.24679","article-title":"Studies of cell-mediated immune responses to influenza vaccination in systemic lupus erythematosus","volume":"60","author":"Holvast","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.imlet.2014.10.008_bib0165","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/art.25033","article-title":"Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximab","volume":"62","author":"van Assen","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.imlet.2014.10.008_bib0170","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1136\/ard.2010.137216","article-title":"EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases","volume":"70","author":"van Assen","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.imlet.2014.10.008_bib0175","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1177\/0961203306069972","article-title":"Traditional and non-traditional risk factors contribute to the development of accelerated artherosclerosis in patients with systemic lupus erythematosus","volume":"15","author":"de Leeuw","year":"2006","journal-title":"Lupus"},{"key":"10.1016\/j.imlet.2014.10.008_bib0180","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.atherosclerosis.2009.03.018","article-title":"Longitudinal study on premature atherosclerosis in patients with systemic lupus erythematosus","volume":"206","author":"de Leeuw","year":"2009","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.imlet.2014.10.008_bib0185","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1002\/art.22568","article-title":"Premature atherosclerotic cardiovascular disease in systemic lupus erythematosus","volume":"56","author":"Westerweel","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.imlet.2014.10.008_bib0190","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1002\/art.21110","article-title":"Prevalence and risk factors for low bone mineral density and vertebral fractures in patients with systemic lupus erythematosus","volume":"52","author":"Bultink","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.imlet.2014.10.008_bib0195","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s12016-012-8320-4","article-title":"Antineutrophil cytoplasmic autoantibodies: how are they detected and what is their use for diagnosis, classification and follow-up?","volume":"43","author":"Cohen Tervaert","year":"2012","journal-title":"Clin Rev Allergy Immunol"},{"issue":"5","key":"10.1016\/j.imlet.2014.10.008_bib0200","first-page":"205","article-title":"Wegener's granulomatosis. A clinicopathological study in twelve patients","volume":"21","author":"van der Woude","year":"1978","journal-title":"Neth J Med"},{"key":"10.1016\/j.imlet.2014.10.008_bib0205","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S0140-6736(85)91147-X","article-title":"Autoantibodies against neutrophils and monocytes: tool for diagnosis and marker of disease activity in Wegener's granulomatosis","volume":"325","author":"Van der Woude","year":"1985","journal-title":"Lancet"},{"key":"10.1016\/j.imlet.2014.10.008_bib0210","first-page":"558","article-title":"Autoantibodies against myeloid lysosomal-enzymes \u2013 a novel class of autoantibodies associated with vasculitic syndromes","volume":"34","author":"Goldschmeding","year":"1988","journal-title":"Kidney Int"},{"issue":"November (5)","key":"10.1016\/j.imlet.2014.10.008_bib0215","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1172\/JCI114335","article-title":"Wegener's granulomatosis autoantibodies identify a novel diisopropylfluorophosphate-binding protein in the lysosomes of normal human neutrophils","volume":"84","author":"Goldschmeding","year":"1989","journal-title":"J Clin Invest"},{"key":"10.1016\/j.imlet.2014.10.008_bib0220","first-page":"270","article-title":"Neutrophil cytoplasmic autoantibodies and Wegener's granulomatosis","volume":"333","author":"Tervaert","year":"1989","journal-title":"Lancet"},{"key":"10.1016\/j.imlet.2014.10.008_bib0225","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1038\/ki.1990.48","article-title":"Autoantibodies against myeloid lysosomal enzymes in crescentic glomerulonephritis","volume":"37","author":"Cohen Tervaert","year":"1990","journal-title":"Kidney Int"},{"key":"10.1016\/j.imlet.2014.10.008_bib0230","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/j.1600-0463.1990.tb05722.x","article-title":"Clinical and histopathological association of 29kD-ANCA and MPO-ANCA","volume":"19","author":"Cohen Tervaert","year":"1990","journal-title":"APMIS Suppl"},{"key":"10.1016\/j.imlet.2014.10.008_bib0235","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1136\/thx.46.1.70","article-title":"Anti-myeloperoxidase antibodies in the Churg\u2013Strauss syndrome","volume":"46","author":"Cohen Tervaert","year":"1991","journal-title":"Thorax"},{"key":"10.1016\/j.imlet.2014.10.008_bib0240","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/0002-9343(91)90074-8","article-title":"Detection of autoantibodies against myeloid lysosomal enzymes: a useful adjunct to classification of patients with biopsy-proven necrotizing arteritis","volume":"91","author":"Cohen Tervaert","year":"1991","journal-title":"Am J Med"},{"key":"10.1016\/j.imlet.2014.10.008_bib0245","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1046\/j.1523-1755.2000.00080.x","article-title":"Antiproteinase 3-and antimyeloperoxidase-associated vasculitis","volume":"57","author":"Franssen","year":"2000","journal-title":"Kidney Int"},{"key":"10.1016\/j.imlet.2014.10.008_bib0250","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1056\/NEJMoa1108735","volume":"367","author":"Lyons","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.imlet.2014.10.008_bib0255","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1001\/archinte.1989.00390110055012","article-title":"Association between active Wegener's granulomatosis and anticytoplasmic antibodies","volume":"149","author":"Tervaert","year":"1989","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.imlet.2014.10.008_bib0260","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/0140-6736(90)92205-V","article-title":"Prevention of relapses in Wegener's granulomatosis by treatment based on antineutrophil cytoplasmic antibody titre","volume":"336","author":"Tervaert","year":"1990","journal-title":"Lancet"},{"key":"10.1016\/j.imlet.2014.10.008_bib0265","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1002\/1529-0131(200009)43:9<2025::AID-ANR13>3.0.CO;2-O","article-title":"Prediction of relapses in Wegener's granulomatosis by measurement of antineutrophil cytoplasmic antibody levels: a prospective study","volume":"43","author":"Boomsma","year":"2000","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.imlet.2014.10.008_bib0270","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1093\/rheumatology\/ker280","article-title":"Value of ANCA measurements during remission to predict a relapse of ANCA-associated vasculitis \u2013 a meta-analysis","volume":"51","author":"Tomasson","year":"2012","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.imlet.2014.10.008_bib0275","article-title":"ANCA as a predictor of a relapse: useful in patients with renal involvement but not in patients with non-renal disease","author":"Kemna","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.imlet.2014.10.008_bib0280","doi-asserted-by":"crossref","first-page":"3209","DOI":"10.1172\/JCI40034","article-title":"Epigenetic basis for aberrant upregulation of autoantigen genes in humans with ANCA vasculitis","volume":"120","author":"Ciavatta","year":"2010","journal-title":"J Clin Invest"},{"key":"10.1016\/j.imlet.2014.10.008_bib0285","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1182\/blood.V98.5.1448","article-title":"Antineutrophil cytoplasm autoantibodies from patients with systemic vasculitis activate neutrophils through distinct signaling cascades: comparison with conventional Fcg receptor ligation","volume":"98","author":"Ben-Smith","year":"2001","journal-title":"Blood"},{"issue":"January (1)","key":"10.1016\/j.imlet.2014.10.008_bib0290","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1097\/BOR.0b013e32834bde57","article-title":"Pathogenesis of ANCA-associated vasculitis: recent insights from animal models","volume":"24","author":"van Timmeren","year":"2012","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.imlet.2014.10.008_bib0295","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1172\/JCI0215918","article-title":"Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice","volume":"110","author":"Xiao","year":"2002","journal-title":"J Clin Invest"},{"key":"10.1016\/j.imlet.2014.10.008_bib0300","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0002-9440(10)62952-5","article-title":"Aggravation of anti-myeloperoxidase antibody-induced glomerulonephritis by bacterial lipopolysaccharide: role of tumor necrosis factor-alpha","volume":"167","author":"Huugen","year":"2005","journal-title":"Am J Pathol"},{"key":"10.1016\/j.imlet.2014.10.008_bib0305","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1182\/blood-2005-03-0921","article-title":"Antineutrophil cytoplasm antibodies directed against myeloperoxidase augment leukocyte-microvascular interactions in vivo","volume":"106","author":"Little","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.imlet.2014.10.008_bib0310","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1136\/ard.2006.064626","article-title":"Rats and mice immunised with chimeric human\/mouse proteinase 3 produce autoantibodies to mouse Pr3 and rat granulocytes","volume":"66","author":"Van der Geld","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.imlet.2014.10.008_bib0315","doi-asserted-by":"crossref","first-page":"e28626","DOI":"10.1371\/journal.pone.0028626","article-title":"Anti-proteinase 3 anti-neutrophil cytoplasm autoantibodies recapitulate systemic vasculitis in mice with a humanized immune system","volume":"7","author":"Little","year":"2012","journal-title":"PLoS ONE"},{"issue":"1","key":"10.1016\/j.imlet.2014.10.008_bib0320","doi-asserted-by":"crossref","first-page":"12","DOI":"10.7326\/0003-4819-120-1-199401010-00003","article-title":"Nasal carriage of staphylococcal infection in Wegener granulomatosis","volume":"120","author":"Stegeman","year":"1994","journal-title":"Ann Internal Med"},{"issue":"May (5 Pt 1)","key":"10.1016\/j.imlet.2014.10.008_bib0325","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/S0091-6749(99)70434-3","article-title":"Differential B- and T-cell activation in Wegener's granulomatosis","volume":"103","author":"Popa","year":"1999","journal-title":"J Allergy Clin Immunol"},{"issue":"August (8)","key":"10.1016\/j.imlet.2014.10.008_bib0330","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1136\/annrheumdis-2012-202986","article-title":"Regulatory B cells in ANCA-associated vasculitis","volume":"72","author":"Wilde","year":"2013","journal-title":"Ann Rheum Dis"},{"issue":"June (6)","key":"10.1016\/j.imlet.2014.10.008_bib0335","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1002\/art.22692","article-title":"Functional defect of circulating regulatory CD4+ T cells in patients with Wegener's granulomatosis in remission","volume":"56","author":"Abdulahad","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"July (7)","key":"10.1016\/j.imlet.2014.10.008_bib0340","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1093\/rheumatology\/kes034","article-title":"Aberrant expression of the negative costimulator PD-1 on T cells in granulomatosis with polyangiitis","volume":"51","author":"Wilde","year":"2012","journal-title":"Rheumatology (Oxford)"},{"issue":"October (5)","key":"10.1016\/j.imlet.2014.10.008_bib0345","doi-asserted-by":"crossref","first-page":"R227","DOI":"10.1186\/ar4066","article-title":"Th17 expansion in granulomatosis with polyangiitis (Wegener's): the role of disease activity, immune regulation and therapy","volume":"14","author":"Wilde","year":"2012","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"10.1016\/j.imlet.2014.10.008_bib0350","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1186\/ar2923","article-title":"T cells in ANCA-associated vasculitis: what can we learn from lesional versus circulating T cells?","volume":"12","author":"Wilde","year":"2010","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.imlet.2014.10.008_bib0355","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1056\/NEJMoa020286","article-title":"A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies","volume":"349","author":"Jayne","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.imlet.2014.10.008_bib0360","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa0909169","article-title":"Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis","volume":"363","author":"Jones","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.imlet.2014.10.008_bib0365","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa0909905","article-title":"Rituximab versus cyclophosphamide for ANCA-associated vasculitis","volume":"363","author":"Stone","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.imlet.2014.10.008_bib0370","doi-asserted-by":"crossref","first-page":"3077","DOI":"10.1093\/ndt\/gfr507","article-title":"Rituximab in ANCA-associated vasculitis: a revolution?","volume":"26","author":"Cohen Tervaert","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.imlet.2014.10.008_bib0375","article-title":"Plasmapheresis rescue therapy in progressive systemic ANCA-associated vasculitis: single-center results of stepwise escalation of immunosuppression","volume":"February","author":"De Joode","year":"2014","journal-title":"J Clin Apher"},{"key":"10.1016\/j.imlet.2014.10.008_bib0380","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/ki.2010.472","article-title":"New pathophysiological insights and treatment of ANCA-associated vasculitis","volume":"79","author":"Wilde","year":"2011","journal-title":"Kidney Int"},{"key":"10.1016\/j.imlet.2014.10.008_bib0385","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1038\/sj.ki.5002103","article-title":"Inhibition of complement factor C5 protects against anti-myeloperoxidase antibody-mediated glomerulonephritis in mice","volume":"71","author":"Huugen","year":"2007","journal-title":"Kidney Int"},{"key":"10.1016\/j.imlet.2014.10.008_bib0390","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/ndt\/gfs428","article-title":"Improved outcome in anti-neutrophil cytoplasmic antibody (ANCA)-associated glomerulonephritis: a 30-year follow-up study","volume":"28","author":"Hilhorst","year":"2013","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.imlet.2014.10.008_bib0395","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.2215\/CJN.01020113","article-title":"Renal survival in proteinase 3 and myeloperoxidase ANCA-associated systemic vasculitis","volume":"8","author":"De Joode","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"issue":"March","key":"10.1016\/j.imlet.2014.10.008_bib0400","doi-asserted-by":"crossref","first-page":"14","DOI":"10.2174\/1874312900903010014","article-title":"ANCA-positive patients: the influence of PR3 and MPO antibodies on survival rate and the association with clinical and laboratory characteristics","volume":"3","author":"Drooger","year":"2009","journal-title":"Open Rheumatol J"},{"key":"10.1016\/j.imlet.2014.10.008_bib0405","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.berh.2012.12.004","article-title":"Cardiovascular disease due to accelerated atherosclerosis in systemic vasculitides","volume":"27","author":"Cohen Tervaert","year":"2013","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"10.1016\/j.imlet.2014.10.008_bib0410","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1093\/rheumatology\/ken035","article-title":"Venous thromboembolism in ANCA-associated vasculitis\u2014incidence and risk factors","volume":"47","author":"Stassen","year":"2008","journal-title":"Rheumatology"},{"key":"10.1016\/j.imlet.2014.10.008_bib0415","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.3899\/jrheum.130200","article-title":"Patients with antineutrophil cytoplasmic antibodies associated vasculitis in remission are hypercoagulable","volume":"40","author":"Hilhorst","year":"2013","journal-title":"J Rheumatol"}],"container-title":["Immunology Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016524781400217X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016524781400217X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,28]],"date-time":"2018-09-28T12:20:26Z","timestamp":1538137226000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016524781400217X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12]]},"references-count":83,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["S016524781400217X"],"URL":"https:\/\/doi.org\/10.1016\/j.imlet.2014.10.008","relation":{},"ISSN":["0165-2478"],"issn-type":[{"value":"0165-2478","type":"print"}],"subject":[],"published":{"date-parts":[[2014,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical immunology \u2013 Autoimmunity in the Netherlands","name":"articletitle","label":"Article Title"},{"value":"Immunology Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.imlet.2014.10.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}